BiotechTube

Osimertinib+cisplatin or carboplatin + pemetrexed Edit

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Non-small Cell Lung Cancer

Conditions

Non-small Cell Lung Cancer

Trial Timeline

May 31, 2026 → May 18, 2030

NCT ID
NCT07279935

About Osimertinib+cisplatin or carboplatin + pemetrexed Edit

Osimertinib+cisplatin or carboplatin + pemetrexed Edit is a approved stage product being developed by AstraZeneca for Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07279935. Target conditions include Non-small Cell Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Non-small Cell Lung Cancer were approved

Approved (20) Terminated (2) Active (0)
✅pemetrexedEli LillyApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅Gefitinib + gemcitabine + carboplatinAstraZenecaApproved
✅PembrolizumabMerckApproved
✅zoledronic acidNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07279935ApprovedRecruiting

Competing Products

20 competing products in Non-small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
pemetrexed + erlotinibEli LillyPhase 2
35
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
LY2875358 + ErlotinibEli LillyPhase 2
35
AdjuvantInsight Molecular DiagnosticsPre-clinical
8
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
Enzastaurin HCLEli LillyPhase 2
35
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
25
pemetrexed + gemcitabineEli LillyPhase 2
35
ALIMTA + CarboplatinEli LillyPhase 2
35
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
29
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
47